18 results
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
a qualified person responsible for oversight, submit safety reports to the regulators and comply with the good pharmacovigilance practice guidelines … on deliverables, timelines, roles & responsibilities, and oversight of conduct of the studies. In addition to GCPs, our clinical trials must
6-K
EX-99.1
GLPG
Galapagos NV
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
collection and CAR-T infusion), and greater physicians oversight throughout the process.
About Relapsed/refractory multiple myeloma (rrMM)
Multiple myeloma
6-K
EX-99.1
GLPG
Galapagos NV
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
and CAR-T infusion), and greater physicians oversight throughout the process.
About the EUPLAGIA-1 study (EudraCT 2021-003815-25)EUPLAGIA-1 is an ongoing
6-K
EX-99.3
kguw tb3hk
11 May 21
Current report (foreign)
2:10pm
6-K
EX-99.1
z22hpliqf1z5 1lqgc
25 Mar 21
Galapagos appoints Bart Filius as President and Chief Operating Officer
6:00am
6-K
EX-99.2
2azw9
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
6-K
EX-99.3
h4gdxsp465 v5
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
20-F
umypy
25 Mar 16
Annual report (foreign)
12:00am
DRS/A
EX-10
mlgde ycjbndvnzir7r1
4 Mar 15
Draft registration statement (amended)
12:00am
DRS/A
EX-10
cel3u85b
4 Mar 15
Draft registration statement (amended)
12:00am
DRS
ph6bzn95j7dm
6 Feb 15
Draft registration statement
12:00am
- Prev
- 1
- Next